<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979767</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY#00145638</org_study_id>
    <nct_id>NCT04979767</nct_id>
  </id_info>
  <brief_title>Function of Circulating Exosomes in Sepsis-induced Immunosuppression</brief_title>
  <official_title>Function of Circulating Exosomes in Sepsis-induced Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center prospective bio-specimen analysis and observational study aiming to&#xD;
      define immune pathways disrupted in bacterial sepsis and to identify clinically useful&#xD;
      biomarkers of immune status.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>28-day mortality</measure>
    <time_frame>From enrollment to 28 days</time_frame>
    <description>All-cause mortality</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>From enrollment until hospital discharge, up to 90 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>From enrollment to 90 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>From enrollment until hospital discharge, up to 90 days</time_frame>
    <description>Hospital length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of infection</measure>
    <time_frame>From enrollment until resolution of SIRS, up to 90 days</time_frame>
    <description>Time to resolution of infection</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Sepsis Syndrome</condition>
  <condition>Sepsis Bacterial</condition>
  <condition>Sepsis, Severe</condition>
  <condition>Sepsis Bacteremia</condition>
  <arm_group>
    <arm_group_label>Sepsis</arm_group_label>
    <description>I. ≥ 50 years with ≥ 2 chronic comorbidities II. Highly suspected bacterial infection based on clinical or radiologic evidence III. ≥ 2 systemic inflammatory response syndrome (SIRS) criteria IV. Actual/anticipated admission to intensive care unit (ICU) V. Anticipated length of hospital stay ≥ 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>I. ≥ 50 years with ≥ 2 chronic comorbidities II. No suspected bacterial infection III. Actual/anticipated admission to intensive care unit (ICU) IV. Anticipated length of hospital stay ≥ 5 days</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood, Plasma, PBMCs, Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized adult patients admitted to the intensive care unit with sepsis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 50 years with ≥ 2 chronic comorbidities&#xD;
&#xD;
          -  Highly suspected bacterial infection based on clinical or radiologic evidence&#xD;
&#xD;
          -  ≥ 2 systemic inflammatory response syndrome (SIRS) criteria&#xD;
&#xD;
          -  Actual/anticipated admission to intensive care unit (ICU)&#xD;
&#xD;
          -  Anticipated length of hospital stay ≥ 5 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Underlying immunosuppression (solid organ transplant, hematopoietic stem cell&#xD;
             transplant, neutropenia, HIV infection, long-term corticosteroid use (≥ 20 mg&#xD;
             prednisone equivalents for ≥ 14 days), immunosuppressants, radiation, chemotherapy,&#xD;
             immune-modifying biologics, viral hepatitis, or systemic autoimmune diseases)&#xD;
&#xD;
          -  Current immunotherapy use&#xD;
&#xD;
          -  Confirmed COVID-19 infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas S Britt, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luigi R Boccardi, BS</last_name>
    <phone>913-588-4022</phone>
    <email>lboccardi@kumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vaughn D Craddock, BS</last_name>
    <phone>316-708-7352</phone>
    <email>vcraddock2@kumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi R Boccardi, BS</last_name>
      <phone>913-588-4022</phone>
      <email>lboccardi@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Vaughn D Craddock, BS</last_name>
      <phone>316-708-7352</phone>
      <email>vcraddock2@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Leslie A Spikes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Navneet K Dhillon, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 16, 2021</last_update_submitted>
  <last_update_submitted_qc>July 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kansas Medical Center</investigator_affiliation>
    <investigator_full_name>Nicholas Britt</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

